California will become the first U.S. state to sell its own branded insulin; a move aimed at lowering drug costs and improving access for residents with diabetes.
The state’s CalRx program, launching in January 2026, will offer long-acting insulin pens at a suggested retail price of $55 for a five-pack, or about $11 per pen.
Pharmacies will purchase the product for $45. The insulin will be interchangeable with glargine, the generic equivalent of Lantus, and patients will not need a new prescription to use the state-branded version.
On Oct. 16, Gov. Gavin Newsom emphasized the state’s action on insulin affordability.
“California didn’t wait for the pharmaceutical industry to do the right thing — we took matters into our own hands,” said Newsom. “No Californian should ever have to ration insulin or go into debt to stay alive.”
The program grew out of a partnership with nonprofit Civica Rx and Biocon Biologics, which will produce insulin under the state label. In 2023, the state allocated $50 million toward the initiative, which has been in development for several years.
CalRx also plans to expand into other essential medications, including asthma and weight-loss drugs, according to Newsom’s office.
Supporters say the initiative could reshape the insulin market by providing a low-cost, state-backed alternative to prices set by major pharmaceutical companies. Analysts note that California’s move could pressure the private sector to lower prices nationwide, though some caution it may prompt market adjustments in response to the state’s intervention.
CalRx represents a bold effort to make life-saving medication more affordable for Californians, particularly those struggling with high insulin costs. State officials say the program could serve as a national model if successful, signaling a new approach for states seeking to expand access to essential drugs while challenging entrenched pharmaceutical pricing practices.